In the spring of 2015, Kevin Gosnell was diagnosed with ALS. His world turned upside down.

A few short months later, Kevin visited the ALS Therapy Development Institute, not just to learn about the mission and work of the organization, but to share with us his vision of bringing key players in the ALS space together to find a treatment for ALS in four years or less.

Such a partnership had never existed.

"Solutions to complex problems are solved through collaboration of great minds. I applaud and the other participants and look forward to faster successful results from ALS ONE," said José Cofiño, a person with ALS and National Ambassador, upon hearing of the new research partnership entered into by the funded ALS Therapy Development Institute.

Welcome to ALS ONE, a partnership between the ALS Therapy Development Institute, Massachusetts General Hospital/Harvard Medical School and the University of Massachusetts Medical School. The partnership is focused on one goal: identify a treatment for ALS. ALS ONE is led by Dr. Robert Brown (UMass), Dr. Merit Cudkowicz (MGH) and Dr. Steve Perrin (ALS Therapy Development Institute). Together, this team has identi­fied the strongest therapeutic opportunities in ALS and are working together as partners to expedite progress toward a treatment, including the sharing of ideas and division of responsibility to advance research projects forward. The ALS ONE model is also set up to contribute a percentage of funds to Compassionate Care ALS, and the clinics at UMass and MGH, to assist people living with the disease until a treatment is available.

"It is so inspiring to see that the ALS Therapy Development Institute continues to be the example of collaboration and transparency in the ALS research community," added Matt Bellina (USN-Ret), a person with ALS and National Ambassador, after hearing about ALS ONE.

Learn more about ALS ONE at or email us at